Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.

Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.

However, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.